Simcere Enters Co-development Partnership With San Francisco Biotech Outfit On Monoclonal Antibody Treatment, Scans China For Takeover Targets

BEIJING - While reporting a strong rise in earnings for 2008, the leaders of China's Simcere Pharmaceutical Group said they have signed a co-development deal with a San Francisco biotech firm on a monoclonal antibody treatment for cancer